| Item type |
itemtype_ver1(1) |
| 公開日 |
2021-12-03 |
| タイトル |
|
|
タイトル |
Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors |
|
言語 |
en |
| 著者 |
Saito, Takuro
Kurose, Koji
Kojima, Takashi
Funakoshi, Takeru
Sato, Eiichi
Nishikawa, Hiroyoshi
Nakajima, Jun
Seto, Yasuyuki
Kakimi, Kazuhiro
Iida, Shinsuke
Doki, Yuichiro
Oka, Mikio
Ueda, Ryuzo
Wada, Hisashi
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利 |
|
|
言語 |
en |
|
権利情報Resource |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
権利情報 |
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
solid cancer patients |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
mogamulizumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
regulatory T cells |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
clinical trial |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
CCR4 |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Tregs infiltrate tumors and inhibit antitumor immunity. KW-0761 (Mogamulizumab) is a humanized anti-CCR4 monoclonal antibody that could eliminate activated Tregs with high immunosuppressive activity that express CCR4. In this phase Ib trial, KW-0761 was used as a cancer immunotherapeutic reagent to deplete Tregs in patients with advanced or recurrent solid CCR4-negative tumors. Thirty-nine patients with solid cancer were treated with KW-0761 at a dose of 0.1 or 1.0 mg/kg. The safety, clinical responses, and effects of Treg depletion were analyzed. Any grade and grade 3–4 treatment-related adverse events (AEs) were observed in 36 (92%) and 14 (36%) out of 39 patients, respectively. All treatment-related AEs were manageable. One and 5 patients achieved a partial response and stable disease, respectively, during treatment and were long survivors. The efficient depletion of Treg in peripheral blood was confirmed in both cohorts. Therefore, the administration of KW-0761 was safe, resulting in the depletion of Tregs in peripheral blood and potential immune responses in patients with solid cancer. The combined use of KW-0761 to deplete Tregs and other immunotherapies is a promising approach to augment immune responses. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Nagoya University Graduate School of Medicine, School of Medicine |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプresource |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| ID登録 |
|
|
ID登録 |
10.18999/nagjms.83.4.827 |
|
ID登録タイプ |
JaLC |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/834.html |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0027-7622 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2186-3326 |
| 書誌情報 |
en : Nagoya Journal of Medical Science
巻 83,
号 4,
p. 827-840,
発行日 2021-11
|
15-2_Saito.pdf (548 KB)
.png)
